CBD is not a registered FDA approved OTC drug - Epidiolex is the only one globally
Last quarter return Epidiolex/Epidyolex net product sales increased 15% to $202.2 million in 2Q23 compared to the same period in 2022. IHL CBD / dronabinol drug candidates make Epidiolex look like an aspirin for a broken leg by comparison check out the data to date - you'll find this is correct Apnimed is a joke by comparison
that is the major opportunity for this company - the regulatory space is empty
there is no market competitor that will get close to this company when approvals start popping
FDA green light out of trials is based on data risk benefit analysis measured against placebo - 45/55 is the go button on that analysis every data point delivered in the CBD arena by these guys to this point has been significantly better than that risk benefit
that is the business case for this penny stock- $$$$$$$
the market has no relationship to that business opportunity - there is no SP bottom and no top
opportunity knocks for those who get it
those who don't can please themselves
glah
IHL Price at posting:
8.2¢ Sentiment: None Disclosure: Held
